Figure 1 shows hazard ratios between biomarker levels and all-cause mortality during each follow-up interval. Hazard ratios indicate the relative risk for death corresponding to a 1-unit increase in log1.5(biomarker level) (that is, a 50% relative difference in biomarker level), after adjustment for age, sex, race, cardiovascular diseases, cancer, diabetes, smoking, and ankle–brachial index. Higher levels of d-dimer, CRP, and serum amyloid A were associated with higher all-cause mortality among patients who died within 1 year after biomarker measurement (hazard ratio, 1.20 [CI, 1.08 to 1.33], 1.13 [CI, 1.05 to 1.21], and 1.12 [CI, 1.04 to 1.20], respectively; P < 0.001, P < 0.001, and P = 0.003) and among patients who died 1 to 2 years after biomarker measurement (hazard ratio, 1.14 [CI, 1.02 to 1.27], 1.15 [CI, 1.06 to 1.24], and 1.13 [CI, 1.04 to 1.24]; P = 0.022, P = 0.001, and P = 0.005]). Higher biomarker levels were not associated with greater all-cause mortality 2 to 3 years after measurement (Figure 1). Table 3 shows average levels of each biomarker at baseline and each follow-up visit, according to when participants died. Among decedents, d-dimer levels were highest at the visit immediately preceding death (Table 3). Findings were similar, but less consistent, for CRP and serum amyloid A.